TickerFacts.

Korro Bio, Inc. (KRRO): Revenue

Annual figures by period end, from SEC filings.

$6.39M
Year ended 2025-12-31
$2.38M
Trailing 12 months to 2026-06-30
2023-12-31: $02024-12-31: $2.27M2025-12-31: $6.39M$6.39M
2023-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$6.39M+181.5%2026-03-12, From 2025-01-01
2024-12-31$2.27Mn/a2026-03-12, From 2024-01-01
2023-12-31$0n/a2025-03-18, From 2023-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Korro Bio, Inc. (KRRO)2025-12-31$6.39M+181.5%
Immunome Inc. (IMNM)2025-12-31$6.94M-23.2%
Whitehawk Therapeutics, Inc. (WHWK)2025-12-31$7.14M-72.5%
Ovid Therapeutics Inc. (OVID)2025-12-31$7.25Mn/m
Xenon Pharmaceuticals Inc. (XENE)2025-12-31$7.50Mn/a
Adagene Inc. (ADAG)2025-12-31$7.67Mn/m
Bolt Biotherapeutics, Inc. (BOLT)2025-12-31$7.70M+0.1%
Aclaris Therapeutics, Inc. (ACRS)2025-12-31$7.83M-58.2%
Coya Therapeutics, Inc. (COYA)2025-12-31$7.95M+123.6%

Compare KRRO, IMNM, WHWK, OVID side by side · Screen every company in Pharmaceutical Preparations ↗